Entry into a Material Definitive

Effective October 13, 2016, Spotlight Innovation Inc. (the Company) entered into an Exclusive License Agreement with Indiana University Research and Technology Corporation to commercialize STL-182, an orally-available small molecule that may have therapeutic potential for treating Spinal Muscular Atrophy.

Item 1.02 Termination of a Material Definitive Agreement.

On October 12, 2016 the Company entered into a Termination Agreement (the Termination Agreement) with Memcine Pharmaceuticals, Inc. (Memcine), the University of Iowa Research Foundation, and Dr. Tony Vanden Bush. Pursuant to the Termination Agreement the Company terminated and cancelled all of its interest in Memcine, terminated the shareholder agreement of Memcine, and John Krohn and Cristopher Grunewald resigned as officers and directors of Memcine.

Item 8.01 Other Events.

On October 14, 2016, the Company issued a Company Overview that it plans to present to potential and existing investors and that will be given at the Fall See Thru Equity Microcap Investor Conference in New York City on October 17, 2016. A copy of this Company Overview is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The Company Overview is also posted on the Companys website, at www.spotlightinnovation.com/investors.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following documents are filed as Exhibits:

Exhibit

Description

10.34

Termination Agreement dated October 12, 2016 between Spotlight Innovation Inc. Memcine Pharmaceuticals, Inc., the University of Iowa Research Foundation, and Dr. Tony Vanden Bush.

99.1

Company Overview dated October 2016.*

________

*Furnished as an Exhibit pursuant to Item 8.01 hereof.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SPOTLIGHT INNOVATION INC.

Dated: October 14, 2016

By:

/s/ Cristopher Grunewald

Cristopher Grunewald, President and CEO

3

EXHIBIT INDEX

Item 9.01 Financial Statements and Exhibits.

(d) Exhibit

The following documents are filed as Exhibits:

Exhibit

Description

10.34

Termination Agreement dated October 12, 2016 between Spotlight Innovation Inc. Memcine Pharmaceuticals, Inc., the University of Iowa Research Foundation, and Dr. Tony Vanden Bush.

99.1

Company Overview dated October 2016.*

____________

*Furnished as an Exhibit pursuant to Item 8.01 hereof.

4

makes a similar move, sign up!

Other recent filings from the company include the following:

SPOTLIGHT INNOVATION, INC. insider just picked up 75,000 shares - Sept. 11, 2017
SPOTLIGHT INNOVATION, INC. insider just picked up 31,250 shares - Sept. 11, 2017

Auto Refresh

Feedback